Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
No agent is known to have efficacy in patients with incurable HNSCC that progressed with prior platin, 5‐FU, cetuximab and taxane. Herein lies the unmet need to be addressed by this trial. Based on the preclinical and clinical data presented, the investigators propose that mitomycin C will have anti‐tumor activity in these patients.
Epistemonikos ID: ee6a85f3dfcb3828aca69367c2bf4c7583cbfe67
First added on: May 12, 2024